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Background: Electronic decision support is commonplace in medical practice. However, its adoption at the
point-of-care is dependent on a range of organisational, patient and clinician-related factors. In particular, level of
clinical experience is an important driver of electronic decision support uptake. Our objective was to examine
the way in which Australian doctors at different stages of medical training use a web-based oncology system
(www.eviq.org.au).
Methods: We used logfiles to examine the characteristics of eviQ registrants (2009–2012) and patterns of eviQ
use in 2012, according to level of medical training. We also used a web-based survey to evaluate the way doctors
at different levels of medical training use the online system and to elicit perceptions of the system’s utility in
oncology care.
Results: Our study cohort comprised 2,549 eviQ registrants who were hospital-based medical doctors across all
levels of training. 65% of the cohort used eviQ in 2012, with 25% of interns/residents, 61% of advanced oncology
trainees and 47% of speciality-qualified oncologists accessing eviQ in the last 3 months of 2012. The cohort
accounted for 445,492 webhits in 2012. On average, advanced trainees used eviQ up to five-times more than other
doctors (42.6 webhits/month compared to 22.8 for specialty-qualified doctors and 7.4 webhits/month for interns/
residents). Of the 52 survey respondents, 89% accessed eviQ’s chemotherapy protocols on a daily or weekly basis in
the month prior to the survey. 79% of respondents used eviQ at least weekly to initiate therapy and to support
monitoring (29%), altering (35%) or ceasing therapy (19%). Consistent with the logfile analysis, advanced oncology
trainees report more frequent eviQ use than doctors at other stages of medical training.
Conclusions: The majority of the Australian oncology workforce are registered on eviQ. The frequency of use
directly mirrors the clinical role of doctors and attitudes about the utility of eviQ in decision-making. Evaluations of
this kind generate important data for system developers and medical educators to drive improvements in
electronic decision support to better meet the needs of clinicians. This end-user focus will optimise the uptake of
systems which will translate into improvements in processes of care and patient outcomes.
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Evidence-based practice is the cornerstone of modern
medicine. Rapid advances in medicine and information
technology have provided the necessary impetus for the
development and deployment of electronic decision sup-
port systems [1-3]. These systems synthesise large bodies
of evidence, a task beyond that of individual clinicians.
Electronic decision support systems have grown in po-
pularity, play an important role in providing up-to-date
resources for point-of-care use, and have been demon-
strated to improve processes of medical care and patient
outcomes [4-7].
Despite the significant benefits of electronic decision
support, its adoption has been highly variable. Well-
documented barriers to access are organisational, pro-
vider and patient-related [6,8-10]. Importantly, there are
concerns on the part of clinicians, particularly doctors,
that reliance on such systems may lead to deskilling in
decision-making. Moreover, many experienced clinicians
report their practices align with best evidence and that
electronic decision support threatens professional auto-
nomy. Conversely, these systems are more likely to be
used when clinicians perceive they enhance decision-
making and improve practice. As the medical profession
becomes more technologically savvy and the culture
continues to embrace the necessity to have the most up-
to-date evidence at clinicians’ finger tips, some of these
traditional barriers may carry less importance. These
changes are also likely to be more apparent in medical
specialties where new technologies and treatments are
changing rapidly and there is a high risk of adverse pa-
tient outcomes.
Oncology practice is particularly demanding due to
the complex nature of care and the challenges of achie-
ving the delicate balance between maximising treatment
effects and minimising toxicity [11,12]. As such, medical
oncology like many other medical specialties has taken
advantage of web-based technology by developing online
guideline and protocol systems to support clinicians in
their day-to-day practice [13]. However, the rapid pro-
liferation of these online systems globally has not been
accompanied by comprehensive evaluation of their use
and impact in cancer treatments settings.
We have developed a multi-faceted research program
evaluating an Australian web-based oncology system,
eviQ treatments online [13-18]. We have demonstrated
high rates of eviQ adoption by all cancer care health
professionals but the nature and extent of use is highly
dependent on clinicians’ specific roles in cancer care
[14]. Our interview-based study of oncology practitio-
ners found that junior cancer clinicians accessed eviQ
more frequently than their senior counterparts. This fin-
ding is driven mainly by levels of familiarity with treat-
ment practices; many senior doctors felt their experiencenegated the necessity to refer to the protocol system
while junior doctors relied heavily on the program to
guide decision-making [15,16]. Importantly, junior doc-
tors were more inclined to embrace information tech-
nology than their senior colleagues and felt that eviQ
gave them a greater sense of autonomy in their day-
to-day practice.
Our aim is to expand and strengthen our previous re-
search by examining how medical doctors at different
stages of training use eviQ. Specifically, we will examine:
1) Characteristics of medical doctors registered on
eviQ;
2) Patterns and frequency of eviQ use (logfile analysis)
according to level of medical training and years of
oncology experience; and
3) Doctors’ perceptions about how eviQ is used in
clinical practice (online survey) and how responses
of clinicians in training compare with speciality-
qualified doctors.General methods
Study setting
In Australia, cancer services are funded primarily by
Australia’s universal health care funding arrangements.
Medical and radiation oncology therapies are mostly de-
livered in the ambulatory care (outpatient) setting at
metropolitan hospitals (university-affiliated, tertiary re-
ferral centres covering geographic areas of around 75
square kilometres), regional centres (with catchments up
to 1,200 square kilometres) and rural hospitals (with
catchments up to 3,400 square kilometres). Australia has
over 700 public hospitals with a total of approximately
55,000 beds [19].eviQ cancer treatments online
eviQ (www.eviQ.org.au) is a web-based oncology proto-
col system managed by the Cancer Institute New South
Wales (NSW), a government funded agency established
to improve cancer control. eviQ primarily targets health
professionals involved in implementing cancer care by
providing detailed and extensive instructions on how
to deliver evidence-based treatments safely and appro-
priately. Treatment information encompasses adolescent
and young adult care, cancer genetics, haematology, hae-
mapoietic progenitor cell transplants, medical oncology,
nursing, primary health, palliative care and radiation
oncology. The site comprises over 1,300 protocols, de-
veloped by a consensus process involving specialist
physicians, nurses, pharmacists and allied health practi-
tioners from across Australia. Each protocol undergoes a
comprehensive review every 1 to 2 years. While the pri-
mary eviQ target audience is health professionals, the
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cancer patients and their carers.
Until October 2009 eviQ was known as the Cancer In-
stitute Standard Cancer Treatments Program (CI-SCaT);
the system underwent a major rebuild and rebranding to
better meet the specific needs of health professionals and
patients. The previous platform (CI-SCaT) was taken off-
line on March 31 2010 to allow sufficient opportunity for
users to transition and register on the eviQ website.
Medical training in Australia
In Australia, medical training generally occurs according
to the following pathway; completion of a medical de-
gree (4 to 6 years duration); at least 2 years of general
medical training as an ‘intern/resident’; at least 2 years
training as a ‘registrar’; and training for at least 3 years
as an ‘advanced trainee’ (most of this time is focused on
the doctors chosen medical speciality such as medical
oncology, haematology). Doctors are specialty-qualified
at the completion of their advanced training, at which
time they become ‘fellows’ and ‘staff specialists’.
Doctors can be exposed to oncology practice from the
time of internship when they may rotate through the
specialty as part of their general medical training. Ad-
vanced trainees choosing an oncology specialty will prac-
tice almost exclusively in this field; will most often be
the key interface between patients and the treating me-
dical team; and will also supervise more junior medical
staff. Staff-specialists are ultimately responsible for the
medical team and treatment decisions.
Ethical approval
This study was approved by the Population and Health
Services Research Ethics Committee (HREC/10/CIPHS/
70). We sought a waiver of consent to undertake the log-
file analysis. We obtained informed consent from cancer
clinicians for the completion of the online survey.
Phase 1: eviQ logfile analysis
Methods
Study design
We conducted a retrospective study of Australian me-
dical doctors registered on eviQ between October 2009
(eviQ launch date) and December 2012. We examined
registrant details and patterns of use from web-logfiles
generated from the eviQ platform in 2012. Specifically,
we compared eviQ use in doctors at various stages of
medical training, from intern/resident through to the
most senior doctors, staff specialists.
Data sources and analysis
The eviQ secretariat provided the research team with
access to data from the eviQ platform. Demographic
registrant and logfile data were obtained on-site at theCancer Institute NSW in unit record format (stripped of
personal identifiers such as usernames). The eviQ plat-
form has the capacity to generate data on the charac-
teristics of all registered users including registrant type
(individual clinician or unit registration), role (e.g., med-
ical, nursing, pharmacy), health sector (public, private, or
both), main area of work (e.g., medical oncology, haema-
tology), geographical location of practice, years of oncol-
ogy experience, and source of referral to the eviQ website.
This information is reported by users upon registration
and website registrants are prompted to update this infor-
mation on an annual basis.
The eviQ platform also generates data on logfiles that
monitor webhits, defined as one click anywhere on the
eviQ website. Logfiles can be stratified by any of the
aforementioned variables (e.g., clinician type, years of
oncology experience) and by the time at which the
webhits occur (e.g., time of day, month, year). However,
the current eviQ logfile reports are aggregated and do
not have the capacity to examine clinician-level use. Fur-
ther, our inability to examine variability by clinician
limits any statistical analyses.
Study cohort (Figure 1)
Our cohort included Australian health professionals re-
gistered as individual clinicians and identifying themselves
as medical doctors upon eviQ registration (Figure 1); ap-
proximately 8% of all registrations are medical units [14].
Medical unit registrations were excluded from our current
analysis as they are likely to represent the web-activity of a
group of health professionals with varying roles and years
of clinical experience. We also excluded medical students,
doctors whose level of training could not be determined,
and doctors unlikely to be practicing in the hospital set-
ting (those identifying as general practitioners or primary
care physicians).
Data analysis and reporting
We used Microsoft Excel for logfile analyses and report
on the following for our study cohort:
Registrant characteristics We describe the registrant
characteristics of our study cohort including level of
training (interns/residents, registrars, advanced trainees,
fellow or staff specialists), main area of work, year of
registration, years of oncology experience, health sector,
location (NSW or another Australian state), and eviQ re-
ferral source. We also report on recency of eviQ use in
order to distinguish between frequent and infrequent eviQ
users (login in the last 3 months, 6 months or 12 months
of 2012).
We present this data for all medical doctors in our co-
hort and by level of training; interns/residents, registrars,












Level of training not specified n=76 
Figure 1 Flowchart of study cohort derivation.
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use for our study cohort using logfiles generated in
2012. Importantly, we examined patterns of use from
the launch of eviQ in October 2009 through to Decem-
ber 2012 and noted no trends in use over time with the
exception of reductions in use over the Australian holi-
day periods (December, January). As such, the current
manuscript focused solely on logfiles from the most re-
cent year, 2012.
We report webhits by month (January-December 2012)
using two metrics: raw webhits and rates (defined as
webhits/100 registered medical doctors). The denomi-
nator for our rate analysis was the number of medical
doctors who accessed the website at least once in 2012;
approximately 35% of registrants did not use eviQ in
2012.
We stratified our analyses by the following:
 Level of training: interns/residents, registrars,
advanced trainees, fellows, and staff specialists.
 Years of oncology experience: <2, 2–5, 5–10, and >10
years (categories pre-defined by eviQ website).
We also analysed raw webhits and rates of use by time
of day and day of the week. Our previous logfile analysesof all Australian health professionals demonstrated that
87% of eviQ activity occurred during standard clinic hours
(08:00–18:00, Monday through Friday) [14]. We examined
whether similar patterns are observed in medical doctors
overall and by level of training.
Results
Registrant characteristics (Figure 1, Table 1)
At December 2012, there were 20,526 Australian health
professionals registered on eviQ 3,150 (15.3%) of whom
were medical doctors. After excluding general practi-
tioners, students, and registrants not specifying their level
of training, our cohort consisted of 2,549 medical doctors
(Figure 1).
Doctors were at various stages of oncology training:
interns/residents (21.5%), registrars (26.2%), advanced
trainees (14.0%), fellows (5.3%), and staff specialists
(32.9%) (Table 1). Our cohort worked primarily in
medical oncology (34.5%), followed by haematology
(17.3%), general medicine (17.1%), and radiation on-
cology (13.2%); most worked in the public sector (85.8%).
Years of oncology experience generally matched level of
training; 88.5% of interns had >2 years of oncology experi-
ence and 80% of staff specialists had 5–10 or >10 years of
oncology experience.
Overall, 65.1% of our cohort had used eviQ at
least once during 2012. A greater proportion of ad-
vanced trainees (61.2%) and staff specialists (46.9%)
used eviQ in the last 3 months of 2012 compared
with interns/residents (25.1%), registrars (36.3%), and
fellows (38.5%).
The majority of doctors were referred to eviQ by a
peer or colleague (73.1% overall); this varied by level of
training, ranging from 54.7% (staff specialists) to 89.8%
(interns/residents).
Patterns of use
Webhits by level of training (Figure 2) Our cohort
accounted for 445,492 total webhits in 2012. Staff
specialists and advanced trainees had higher numbers
of raw webhits compared with doctors at other levels
of training; this pattern was consistent across 2012
(Figure 2).
On average, medical doctors had 22.4 hits/month but
rates of use varied by level of training, with advanced
trainees using eviQ up to five times that of other med-
ical doctors. Specifically, advanced trainees had an aver-
age of 42.6 hits/month whereas other groups had fewer
hits/month: interns/residents (7.4 hits/month), registrars
(20.0 hits/month), fellows (18.4 hits/month) and staff
specialists (22.8 hits/month). This pattern was consistent
across 2012. Further, based on our previous research
demonstrating that 9 pages are viewed during a typical
user session [14], we can approximate that on average,













Main area of work n % n % n % n % n % n %
Medical oncology 879 34.5 207 37.7 190 28.4 145 40.5 40 29.6 297 35.4
Haematology 440 17.3 80 14.6 67 10.0 94 26.3 19 14.1 180 21.5
General medicine 435 17.1 174 31.7 223 33.3 12 3.4 6 4.4 20 2.4
Radiation oncology 336 13.2 25 4.6 97 14.5 45 12.6 23 17.0 146 17.4
Palliative care 117 4.6 6 1.1 16 2.4 32 8.9 8 5.9 55 6.6
Other* 137 5.4 14 2.6 45 6.7 8 2.2 18 13.3 52 6.2
Missing 205 8.0 43 7.8 31 4.6 22 6.1 21 15.6 88 10.5
Year of registration
2009 177 6.9 3 0.5 15 2.2 40 11.2 11 8.1 108 12.9
2010 875 34.3 110 20.0 179 26.8 131 36.6 53 39.3 402 48.0
2011 712 27.9 196 35.7 209 31.2 88 24.6 30 22.2 189 22.6
2012 785 30.8 240 43.7 266 39.8 99 27.7 41 30.4 139 16.6
Oncology experience
<2 years 1111 43.6 486 88.5 408 61.0 174 48.6 17 12.6 26 3.1
2–5 years 520 20.4 45 8.2 185 27.7 141 39.4 51 37.8 98 11.7
5–10 years 304 11.9 4 0.7 49 7.3 35 9.8 30 22.2 186 22.2
> 10 years 529 20.8 0 0.0 8 1.2 3 0.8 34 25.2 484 57.8
Missing 85 3.3 14 2.6 19 2.8 5 1.4 3 2.2 44 5.3
Health sector
Public 2187 85.8 531 96.7 619 92.5 349 97.5 95 70.4 593 70.8
Private 150 5.9 7 1.3 28 4.2 2 0.6 24 17.8 89 10.6
Both public and private 209 8.2 11 2.0 22 3.3 7 2.0 15 11.1 154 18.4
Missing 3 0.1 0 0.0 0 0.0 0 0.0 1 0.7 2 0.2
Location
NSW 1000 39.2 158 28.8 257 38.4 177 49.4 59 43.7 349 41.6
Other Australian states 1549 60.8 391 71.2 412 61.6 181 50.6 76 56.3 489 58.4
Recency of use
Last 3 months of 2012 1045 41.0 138 25.1 243 36.3 219 61.2 52 38.5 393 46.9
Last 6 months of 2012 1311 51.4 211 38.4 316 47.2 250 69.8 72 53.3 462 55.1
Any time during 2012 1659 65.1 306 55.7 424 63.4 285 79.6 90 66.7 554 66.1
No use in 2012 890 34.9 243 44.3 245 36.6 73 20.4 45 33.3 284 33.9
Referral source
Peer/colleague 1863 73.1 493 89.8 544 81.3 275 76.8 93 68.9 458 54.7
Cancer Institute communication 257 10.1 4 0.7 19 2.8 36 10.1 8 5.9 190 22.7
Conference/booth 49 1.9 3 0.5 12 1.8 6 1.7 5 3.7 23 2.7
Internet 93 3.6 10 1.8 23 3.4 17 4.7 7 5.2 36 4.3
Professional organisation 131 5.1 10 1.8 36 5.4 10 2.8 11 8.1 64 7.6
eviQ education session 102 4.0 23 4.2 25 3.7 9 2.5 6 4.4 39 4.7
Other 54 2.1 6 1.1 10 1.5 5 1.4 5 3.7 28 3.3
*Other: Includes genetics, adolescent, paediatrics.
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other doctors appear to use the site on a fortnightly
or monthly basis.Webhits by years of oncology experience (Figure 3)
Raw webhits by years of oncology experience were pro-
portional to the size of the clinician groups; clinicians
Figure 2 Webhits by level of training during 2012. A) Raw
webhits; B) Rates of use: hits per 100 medical doctors that accessed
eviQ during 2012.
Figure 3 Webhits by years of oncology experience in 2012.
A) Raw webhits; B) Rates of use: hits per 100 medical doctors that
accessed eviQ during 2012.
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number of webhits, followed by clinicians with 2–5
years, >10 and 5–10 years of experience; patterns were
consistent during the 12 month study period (Figure 3).
In contrast to our analysis by level of training, our rate
analysis demonstrated less variation in eviQ use by years
of oncology experience; mean hits per clinician/month
ranged from 17.0 (>10 years’ experience) to 25.9 (2–5
years’ experience) This most likely reflects the fact that
professional role (rather than years of oncology experi-
ence) determines the nature of doctors’ patient load and
thus the utility of eviQ in day-to-day practice. For ex-
ample, advanced trainees specialising in oncology are
likely to see substantially more cancer patients than in-
terns or registrars that rotate across more diverse areas of
medicine.
Webhits by time of day (Figure 4) Our cohort used
eviQ primarily during standard clinic hours, with 87.7%
of all webhits occurring between 08:00–18:00 Monday to
Friday; this pattern of use was similar across all levels of
training (Figure 4).Phase 2: Online survey of medical doctors
Methods
Study design
Our objective was to compare how eviQ is used by clini-
cians in training with senior doctors. We developed a 14
item self-report survey to assess doctors’ use of eviQ in
their clinical practice. A link to the survey was on the
eviQ home page for a 7 week period (September-Octo-
ber 2012); this was accompanied with an invitation to
complete the survey. It was estimated that the survey
would take no more than 15 minutes to complete and
was populated on a server external to eviQ (Google
Docs; https://docs.google.com). Upon completion, re-
spondents were invited to send their email address to
the researchers to enter a draw to win an Apple iPad;
delivered to the winner of the draw in November 2012.
Survey respondents
Our target population was Australian medical doctors.
As with phase 1, we excluded survey respondents who
were general practitioners, students, other health profes-
sionals, and those practising outside of Australia.
Figure 4 Webhits by time of day in medical doctors according to level of training in 2012. A) Raw webhits; B) Rates of use: hits per 100
medical doctors that accessed eviQ during 2012.
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The survey was developed based on our previous survey
work [15,16] and in consultation with the eviQ secreta-
riat and was pilot tested with oncologists and medical
students. As such, we established the instrument’s va-
lidity but not reliability. The survey consisted of 14
questions; 13 forced choice and one free-text. We col-
lected demographic details, level of training (questions
1–8) and frequency of use of eviQ tools in the past
month (e.g., chemotherapy protocols; questions 9–11).
We also assessed frequency of eviQ use for clinical tasks
(e.g., guiding chemotherapy administration; question 12)
and the extent to which respondents agreed with 4 state-
ments about eviQ (e.g., “is integral to my clinical prac-
tice”; question 13). Finally, we asked respondents to list
any other computer-based systems or websites they use
to support their clinical practice. See Additional file 1
for a complete version of the survey.
Analysis and reporting
Survey data were analysed using SPSS and Microsoft
Excel. We report demographic details and survey re-
sponses overall and by level of training.
Results
Characteristics of survey respondents (Table 2)
Of 67 survey respondents, 52 were Australian medical
doctors (Table 2). Respondents were at various stages of
their training including interns/residents (n = 9, 17.3%),registrars (n = 13, 25.0%), advanced trainees (n = 15,
28.8%), fellows (n=8, 15.4%) and staff specialists (n = 7,
13.5%). Due to small sample sizes, we describe survey re-
sults for interns/residents/registrars as one group (n=22)
and fellows/staff specialists as one group (n=15). Similar
to the characteristics of all medical doctors registered
with eviQ (phase 1), most respondents worked in med-
ical oncology (57.7%) and the public sector (94.2%). The
majority of respondents used eviQ on a daily basis in the
last month (53.8%), the remainder of respondents used
eviQ weekly (34.6%) or fortnightly (9.6%).
Survey responses (Table 3)
Due to the low survey response rate and small numbers
of respondents according to each level of training, we
present outcomes for all respondents with some general
findings by level of training.
eviQ tools The majority of respondents used eviQ tools
in the past month with the following tools used on a
daily or weekly basis: chemotherapy protocols (88.8%),
assessment tools (69.2%), drug calculator (63.4%), and
clinical procedures (53.8%) (Table 3). Cancer genetics,
patient information, supportive therapy, and discussion
boards were the least frequently used tools (6-40% re-
spondents used these tools on a daily/weekly basis).
Advanced trainees reported using eviQ tools more
frequently than other medical groups. On average, over
70% of advanced trainees (11/15 respondents) used eviQ
Table 2 Characteristics of survey respondents meeting





Advanced trainee 15 28.8
Fellow 8 15.4
Staff specialist 7 13.5
Oncology experience
< 2 years 15 28.8
2–5 years 25 48.1
5–10 years 7 13.5
>10 years 5 9.6
Location
NSW 28 53.8




Both public and private 3 5.8
Main area of work
Medical oncology 30 57.7
Haematology 10 19.2
Radiation oncology 4 7.7
Palliative care 3 5.8
Other* 5 9.6




Not at all 18 1.9
*Other: Includes genetics, adolescent, paediatrics.
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30% of fellow/staff specialists (4/15 respondents) and
just over half of interns/registrars (13/22 respondents).
These results contrast with phase 1, in which interns/
residents had the lowest rates of use. However, survey
respondents had visited the site in the survey period
and were most probably engaged in an oncology rota-
tion at the time. In contrast, the rates of use reported
in phase 1 were based on the logfiles of any doctor
who had accessed the site in 2012. Interns and resi-
dents rotate through different specialties approxima-
tely every 10 weeks during their training and it is
highly unlikely they would access the site when the
rotation is complete.eviQ for clinical tasks Consistent with its primary pur-
pose, eviQ was most commonly used to initiate therapy
(78.9% used eviQ daily or weekly for this task). However,
as previously reported [15,16] eviQ was used for the full
spectrum of cancer care including monitoring (28.8%),
alternating (34.6%), and ceasing therapy (19.2%) on a
daily/weekly basis.
eviQ was used frequently (daily/weekly) for a number
of specific tasks including: comparing treatment options
(57.7%), prescribing medications (50%), calculating drug
doses (65.4%), guiding chemotherapy administration
(73.1%), and to access evidence-based practice informa-
tion (69.3%). eviQ was not routinely used to guide radio-
therapy administration, access treatment cost information,
or as a teaching resource (19.2%, 25.0%, 30.8% repor-
ted using eviQ for these tasks on a daily/weekly basis,
respectively).
Overall, advanced trainees reported using eviQ more
frequently for clinical tasks compared with interns/regis-
trars and staff specialists/fellows; approximately 70% of
advanced trainees compared with 50% of interns/regis-
trars and 25% of staff specialists/fellows.
Clinicians attitudes towards eviQ The majority of re-
spondents viewed eviQ favourably. It was endorsed as an
up-to-date resource (94.2%), integral to clinical practice
(78.9%), and a resource that allows clinicians to function
autonomously (80.8%). Further, 67.3% of respondents
stated that it was their primary source of oncology in-
formation. No respondent 'strongly disagreed' with any
statement.
Unlike the frequency of eviQ use for various clinical
tasks, clinicians’ attitudes toward eviQ were generally
consistent across level of training. Across the four state-
ments, advanced trainees viewed eviQ most favourably
(87-100% agreed/strongly agreed), followed by interns/
registrars (59-96%), and staff specialists/fellows (53-87%).
The greatest variation was in relation to eviQ as a primary
information source; 53% of staff specialists/fellows and
59% of interns/registrars compared with 93% of advanced
trainees agreed/strongly agreed.
Use of other web-based resources 23.1% of respon-
dents listed other online resources they used to support
their oncology practice. These included journals/research
databases, other oncology websites, and hospital-specific
point-of-care programs.
Discussion
Our study complements a large program evaluation of a
web-based oncology protocol system [13-18]. eviQ has
been rated among the highest quality online cancer care
applications internationally [13,18] and is used at the
point-of-care by the key health professionals involved in
Table 3 Survey responses of medical doctors meeting study eligibility criteria (N = 52)
Daily Weekly Fortnightly Not at all
In the past month how often did you use the following eviQ tools? n % n % n % n %
Assessment tools 22 42.3 14 26.9 1 1.9 15 28.8
Cancer genetics 4 7.7 17 32.7 15 28.8 16 30.8
Chemotherapy protocols 26 50.0 15 28.8 9 17.3 2 3.8
Clinical procedures 9 17.3 19 36.5 10 19.2 14 26.9
Patient information 4 7.7 17 32.7 20 38.5 11 21.2
Supportive therapy 4 7.7 13 25.0 20 38.5 15 28.8
Drug calculator 19 36.5 14 26.9 6 11.5 13 25.0
Discussion boards 0 0.0 3 5.8 24 46.2 25 48.1
In the past month how often have you used eviQ to guide the following?
Initiating therapy 16 30.8 25 48.1 7 13.5 4 7.7
Monitoring therapy 2 3.8 13 25.0 23 44.2 14 26.9
Altering therapy 2 3.8 16 30.8 24 46.2 10 19.2
Ceasing therapy 0 0.0 10 19.2 18 34.6 24 46.2
In the past month how often did you use eviQ to:
Compare treatment options 6 11.5 24 46.2 14 26.9 8 15.4
Prescribe medication 8 15.4 18 34.6 14 26.9 12 23.1
Calculate drug dosages 25 48.1 9 17.3 6 11.5 12 23.1
Guide chemotherapy administration 20 38.5 18 34.6 5 9.6 9 17.3
Guide radiotherapy administration 2 3.8 8 15.4 21 40.4 21 40.4
Source treatment cost information 4 7.7 9 17.3 20 38.5 19 36.5
Search for side effects/toxicity 7 13.5 10 19.2 28 53.8 7 13.5
Provide patient information 7 13.5 11 21.2 22 42.3 12 23.1
Teaching resource 5 9.6 11 21.2 15 28.8 21 40.4
Access evidence-based (literature) relevant to practice 11 21.2 25 48.1 9 17.3 7 13.5
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this study, we focus specifically on medical doctors and
their utilization of the system across the spectrum of
medical training. Our multi-method approach builds
upon our previous work and for the first time, allows us
to understand the profile of medical doctors using eviQ
frequently and intermittently.
Our study suggests that eviQ is an integral part of
medical practice in Australia. Importantly, the number
of medical oncologists registered on eviQ is similar to
that reported in a recent audit of the Australian medical
oncology workforce, highlighting the widespread interest
in the system in this group of cancer care professionals
[20]. Further, given global and local concerns about
shortages in the medical oncology workforce [20,21] and
clinician burnout [22], systems like eviQ that synthesise
the growing evidence-base and streamline clinical prac-
tice [15,16] will be increasingly important for the safe
and effective delivery of cancer care.
Our results demonstrate important differences in eviQ
use according to level of medical training. We foundrates of use increase according to level of training and
peak with advanced trainees. After doctors are specialty-
qualified their rates of use decline to match those of reg-
istrars. This is consistent with our previous research that
found doctors in training viewed eviQ as important in
guiding their clinical practice and for professional auto-
nomy. In contrast, specialty-qualified doctors expressed
reservations about routine use of standardised protocols
and were less likely to use the system than their more
junior colleagues [16].
The different patterns of eviQ use observed in this
study directly mirror the roles of clinicians in oncology
care at different levels of training. Specifically, interns,
residents and registrars rotate across medical specialties
and would only generally use eviQ during oncology
terms. Advanced trainees plan to specialise in oncology
and are likely to have the greatest patient load inclu-
ding direct involvement in initiating and monitoring
treatments (under the direct supervision of a specialty-
qualified clinician). Finally, staff specialists generally sub-
specialise in specific cancer treatments (e.g., breast cancer)
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and treatments. They may only use eviQ when faced with
new or unfamiliar clinical situations [15,16]. Nevertheless,
the lower rates of use observed in staff specialists may be
viewed as less than optimal as speciality-qualified doctors
are ultimately responsible for the outcomes of oncology
care. Alternatively, our results may indicate that this group
of doctors remain up-to-date with latest evidence using
other information sources.
Differences in use across levels of training are not
unique to online systems in oncology practice. A large-
scale evaluation of another Australian evidence-based re-
source found junior clinicians were more likely to be
aware of and use the system at the point-of-care than
their senior counterparts [23]. Given that online systems
have been found to improve accuracy and confidence of
clinicians’ decisions [24,25], reticence on the part of se-
nior doctors may reflect their enduring preference to
rely on their own experience or that of their colleagues
as their primary information source for point-of-care de-
cisions [26].
Our targeted analysis of doctors’ use of eviQ at various
stages in their medical training made use of improve-
ments to the eviQ platform since our previous analyses
[14]. Our logfile analysis demonstrated that a significant
proportion of medical registrants are not regular visitors
to the site. As such, the rate analyses presented in the
current study is likely to more accurately reflect current
use of the system (22 hits/doctor vs 14 hits/doctor in
our previously published logfile analysis). Even with im-
provements to the capabilities of the eviQ platform, a
limitation of our study was the inability of the platform
to examine use at an individual doctor level and track
this use over time. Clearly, consideration of these issues
has important implications for the interpretation of eval-
uations of this kind.
A further limitation to our current analysis is the lack
of specificity of the eviQ platform in identifying years of
oncology experience and possible underestimation of
use by medical doctors who may have accessed eviQ
through oncology unit registrations. We have previ-
ously demonstrated that that rates of eviQ use through
unit registrations are three times that of individual cli-
nicians [14]. Moreover, we attempted to complement
our logfile analyses with an online survey but the low
response rates, even when we offered an incentive to
respond, highlights the challenge of gaining insights
from a group of busy doctors, something that needs to
be improved to enhance ongoing monitoring activities.
Additionally, our survey only captured responses from
doctors that used the website during the 7 week win-
dow that the survey was online; as such, it is unlikely
that our sample is representative of all medical doctors
who use eviQ.Conclusion
Electronic decision support systems are undoubtedly the
future of medicine [2]. However, the provision of the
most state-of-the art system does not guarantee uptake,
and this remains an ongoing challenge for contemporary
medical practice. An important consideration is that
these systems should never replace interactions with col-
leagues and patients. Rather, system developers, medical
educators and health care administrators need to con-
sider how these systems best complement such interac-
tions to enhance medical care. Multi-method evaluation
approaches examining end-user attitudes, knowledge
and behaviour will add significant value to achieving this
goal. Importantly, evaluation should also aim to better
understand the way electronic decision support im-
proves real-world processes and outcomes of care to
assess the value for money or cost-effectiveness of their
deployment.
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